Drug profile · INN
oxcarbazepine
TRILEPTAL
oxcarbazepine (TRILEPTAL) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — oxcarbazepine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 16
- Programs
- 3
- Data quality
- 0.89
Quick answer
oxcarbazepine (TRILEPTAL) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11896599
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 11166960
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 10220042
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 9855278
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 9370525
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 9351975
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 9119792
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 9119791
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 8821930
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 8617600
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 8211464
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 8017149
Modified release preparations containing oxcarbazepine and derivatives thereof
granted -
US 7910131
Method of treating seizures using modified release formulations of oxcarbazepine
granted -
US 7722898
Modified-release preparations containing oxcarbazepine and derivatives thereof
granted -
AU 2007242062
Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
granted -
US 7183272
Crystal forms of oxcarbazepine and processes for their preparation
granted
Frequently asked questions
What is oxcarbazepine?
oxcarbazepine (TRILEPTAL) is a sodium channel alpha subunit blocker. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for oxcarbazepine?
TRILEPTAL is a marketed brand name for oxcarbazepine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxcarbazepine?
oxcarbazepine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.